KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Cost of Revenue (2016 - 2023)

Historic Cost of Revenue for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2023 value amounting to $106000.0.

  • TherapeuticsMD's Cost of Revenue fell 7005.65% to $106000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was $106000.0, marking a year-over-year decrease of 9241.23%. This contributed to the annual value of $1.4 million for FY2022, which is 35.66% down from last year.
  • As of Q3 2023, TherapeuticsMD's Cost of Revenue stood at $106000.0, which was down 7005.65% from $354000.0 recorded in Q3 2022.
  • In the past 5 years, TherapeuticsMD's Cost of Revenue ranged from a high of $110.8 million in Q4 2019 and a low of -$84.8 million during Q4 2021
  • Moreover, its 5-year median value for Cost of Revenue was $2.1 million (2019), whereas its average is $12.4 million.
  • Per our database at Business Quant, TherapeuticsMD's Cost of Revenue skyrocketed by 1155132.84% in 2019 and then tumbled by 42616.94% in 2021.
  • TherapeuticsMD's Cost of Revenue (Quarter) stood at $110.8 million in 2019, then plummeted by 76.53% to $26.0 million in 2020, then plummeted by 426.17% to -$84.8 million in 2021, then surged by 100.42% to $354000.0 in 2022, then tumbled by 70.06% to $106000.0 in 2023.
  • Its Cost of Revenue was $106000.0 in Q3 2023, compared to $354000.0 in Q3 2022 and $348000.0 in Q2 2022.